Pirtobrutinib

Pirtobrutinib

Another Name
吡托替尼、吡托布替尼、Jaypirca、LOXO-305
Indications
Used for relapsed/refractory mantle cell lymphoma and other B-cell malignancies.
Reg No
06 L 1110/24
Inspection No
1068-24
dosage form:capsule
Specs:50mg/30Tablets
Indate:24 months
Date：2024-9-1 Views：1080
Drug Info

COMPOSITION:

Each film-coated tablet contains Pirtobrutinib ……………………………. 50 mg.

INDICATION:

LuciPirto is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

DOSAGE AND USE:

The recommended dosage of LuciPirto is 200 mg orally once daily; swallow whole with water, with or without food. Do not cut, crush, or chew tablets.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciPirto during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/pirtobrutinib/

Related News